- Home
- BLUE vs BEAT Comparison
BLUE vs BEAT Comparison
Compare BLUE & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- BEAT
- Stock Information
- Founded
- BLUE 1992
- BEAT 2015
- Country
- BLUE United States
- BEAT United States
- Employees
- BLUE N/A
- BEAT N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- BLUE Health Care
- BEAT Technology
- Exchange
- BLUE Nasdaq
- BEAT Nasdaq
- Market Cap
- BLUE 78.7M
- BEAT 74.1M
- IPO Year
- BLUE 2013
- BEAT 2021
- Fundamental
- Price
- BLUE $8.50
- BEAT $2.43
- Analyst Decision
- BLUE Hold
- BEAT Buy
- Analyst Count
- BLUE 9
- BEAT 1
- Target Price
- BLUE $49.14
- BEAT $8.00
- AVG Volume (30 Days)
- BLUE 729.7K
- BEAT 280.6K
- Earning Date
- BLUE 11-14-2024
- BEAT 11-07-2024
- Dividend Yield
- BLUE N/A
- BEAT N/A
- EPS Growth
- BLUE N/A
- BEAT N/A
- EPS
- BLUE N/A
- BEAT N/A
- Revenue
- BLUE $53,120,000.00
- BEAT N/A
- Revenue This Year
- BLUE $152.71
- BEAT N/A
- Revenue Next Year
- BLUE $233.91
- BEAT N/A
- P/E Ratio
- BLUE N/A
- BEAT N/A
- Revenue Growth
- BLUE 144.50
- BEAT N/A
- 52 Week Low
- BLUE $5.80
- BEAT $1.35
- 52 Week High
- BLUE $38.40
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- BLUE 50.43
- BEAT 39.27
- Support Level
- BLUE $5.97
- BEAT $2.28
- Resistance Level
- BLUE $9.75
- BEAT $3.48
- Average True Range (ATR)
- BLUE 2.04
- BEAT 0.30
- MACD
- BLUE 0.07
- BEAT -0.10
- Stochastic Oscillator
- BLUE 26.83
- BEAT 12.50
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.